

Number 775 • November 2018

# *Alberta Drug Benefit List (ADBL)* Interim Update now available online

Please be advised that the January 1, 2019 Updates to the *Alberta Drug Benefit List (ADBL)* has been posted online at **www.ab.bluecross.ca/dbl/publications.html** 

Please refer to the January 1, 2019 Updates for complete listings of products available by special authorization, products available by step therapy / special authorization and products with changes to criteria for coverage.

Please note that the online *Interactive Drug Benefit List (iDBL)* at **www.ab.bluecross.ca/dbl/idbl\_main1.html** is a near real-time application, and as such, contains the most up-to-date information.

### Product supply shortages addressed for Alberta Drug Benefit List (ADBL)

Alberta Blue Cross has been advised by AA Pharma Inc. that the shortage for Dextroamphetamine 5 mg Tablet (DIN 02443236) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **January 14, 2019.** 

#### **DEXTROAMPHETAMINE SULFATE**

1 % / 5 % TOPICAL GEL

5 MG TABLET			
00002443236	DEXTROAMPHETAMINE	AAP	\$ 0.5081
00001924516	DEXEDRINE	PAL	\$ 0.6251

Alberta Blue Cross has been advised by Taro Pharmaceuticals Inc. that the shortage for Taro-Benzoyl Peroxide/Clindamycin Kit 5%/1% Topical Gel (DIN 02464519) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **January 14, 2019.** 

#### **CLINDAMYCIN PHOSPHATE/ BENZOYL PEROXIDE**

00002464519	TARO-BENZOYL PEROXIDE/CLINDAMYCIN KIT	TAR	\$ 0.7422
00002248472	BENZACLIN	VCL	\$ 0.9954

## Temporary benefit added to the Alberta Drug Benefit List (ADBL)

Due to the unavailability of Altace HCT 5 mg/12.5 mg Tablet (DIN 02283158) manufactured by Valeant Canada LP, Ran-Ramipril HCTZ 5 mg/12.5 mg Tablet (DIN 02449447) manufactured by Ranbaxy Pharmaceuticals Canada Inc., will be considered a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

As of **December 14, 2018**, all claims for Ran-Ramipril HCTZ 5 mg/12.5 mg Tablet (DIN 02449447) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at **www.ab.bluecross.ca/providers/pharmacy-home.html**.

If this situation continues to be a long-term matter then this product is subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics and must be approved by the Minister of Health for addition to the *ADBL* in order to remain as a benefit.

#### When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

**780-498-8370** (Edmonton and area) • **403-294-4041** (Calgary and area) • **1-800-361-9632** (toll free) **FAX 780-498-8406** (Edmonton and area) • **FAX 1-877-305-9911** (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims. **Visit ab.bluecross.ca/providers/pharmacy-home.php** 



\*\*The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. \*† Blue Shield is a registered trade-mark of the Blue Cross Blue Shield Association. ABC 82320.775 2018/12

